Zamristobart
Based on 1 Customer Validation
Zamristobart is an anti-LILRB1 (leukocyte immunoglobulin-like receptor B1) IgG4κ type humanized antibody with immunostimulant and antineoplastic activities. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
For research use only. We do not sell to patients.
- Purity : 96.62%
- CAS No.: 3036192-53-4
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
LILRB1 |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized LILRB1/CD85j/ILT2 Protein, Human (HEK293, His, HY-P70179) can bind Zamristobart. The EC50 for this effect is 54.94 ng/mL.
Chemical Information
-
CAS No. 3036192-53-4
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
SAR-444881; BND-22
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (229 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)